Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 7/20 | 0.77 |
| ▸ | ALOX12 | P18054 | 3/20 | 0.77 |
| ▸ | FOS | P01100 | 1/20 | 0.70 |
| ▸ | TTR | P02766 | 1/20 | 0.70 |
| ▸ | JUN | P05412 | 1/20 | 0.70 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.70 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.70 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.70 |
| ▸ | CA2 | P00918 | 1/20 | 0.63 |
| ▸ | LDHA | P00338 | 1/20 | 0.62 |
| ▸ | ATM | Q13315 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | PPARG | P37231 | 1/20 | 0.53 |
| ▸ | PPARD | Q03181 | 1/20 | 0.53 |
| ▸ | PPARA | Q07869 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Terameprocol SCHEMBL2356280 | 1.00 | ALOX15 (0.77) | ALOX15ALOX12FOSTTRJUN | |
| Terameprocol SCHEMBL29794162 | 1.00 | ALOX15 (0.77) | ALOX15ALOX12FOSTTRJUN | |
| Terameprocol SCHEMBL10060164 | 1.00 | ALOX15 (0.77) | ALOX15ALOX12FOSTTRJUN | |
| Terameprocol SCHEMBL30094578 | 1.00 | ALOX15 (0.77) | ALOX15ALOX12FOSTTRJUN | |
| SCHEMBL4558800 | 0.96 | ALOX15 (0.73) | ALOX15ALOX12FOSTTRJUN | |
| SCHEMBL15160938 | 0.91 | ALOX15 (0.67) | ALOX15ALOX12FOSTTRJUN | |
| SCHEMBL14238533 | 0.91 | ALOX15 (0.67) | ALOX15ALOX12FOSTTRJUN | |
| SCHEMBL14864105 | 0.91 | ALOX15 (0.67) | ALOX15ALOX12FOSTTRJUN | |
| SCHEMBL16323169 | 0.90 | ALOX15 (0.71) | ALOX15ALOX12FOSTTRJUN | |
| SCHEMBL2390 | 0.89 | FOS (0.90) | ALOX15ALOX12FOSTTRJUN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 314 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4363043-B1 | COMPOSITIONS FOR USE IN METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | NOVOCURE GMBH (CH) | 2026-04-22 | — | — | EP | claimed |
| US-12594421-B2 | Compositions and methods for increasing cancer cell sensitivity to alternating electric fields | NOVOCURE GMBH (CH) | 2026-04-07 | — | — | US | claimed |
| US-20250339680-A1 | COMPOSITIONS AND METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | NOVOCURE GMBH (CH) | 2025-11-06 | — | — | US | claimed |
| EP-4640714-A2 | METHODS FOR ASSESSING RISK OF DEVELOPING A VIRAL DISEASE USING A GENETIC TEST | PML Screening, LLC (US) | 2025-10-29 | — | — | EP | claimed |
| US-20250242086-A1 | THERAPEUTIC BIOMATERIAL THAT ATTENUATES THE FOREIGN BODY RESPONSE | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2025-07-31 | — | — | US | claimed |
| US-12350261-B2 | Methods and devices for the treatment of ocular diseases in human subjects | CLEARSIDE BIOMEDICAL, INC. (US) | 2025-07-08 | — | — | US | claimed |
| WO-2024199144-A1 | NOVEL REAGENT FOR MITIGATING LNP TOXICITY | SHANGHAI MOYIN THERAPEUTICS CO., LTD. (CN) | 2024-10-03 | — | — | WO | claimed |
| EP-4363043-A1 | COMPOSITIONS AND METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | Novocure GmbH (CH) | 2024-05-08 | — | — | EP | claimed |
| EP-4177356-B1 | METHODS FOR ASSESSING RISK OF DEVELOPING A VIRAL DISEASE USING A GENETIC TEST | PML SCREENING LLC (US) | 2024-05-08 | — | — | EP | claimed |
| CN-117580614-A | Compositions and methods for increasing sensitivity of cancer cells to alternating electric fields | 诺沃库勒有限责任公司 | 2024-02-20 | — | — | CN | claimed |
| EP-4177356-A1 | METHODS FOR ASSESSING RISK OF DEVELOPING A VIRAL DISEASE USING A GENETIC TEST | PML Screening, LLC (US) | 2023-05-10 | — | — | EP | claimed |
| WO-2023275649-A1 | COMPOSITIONS AND METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | NOVOCURE GMBH (CH) | 2023-01-05 | — | — | WO | claimed |
| US-20230001193-A1 | COMPOSITIONS AND METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | BIOPHARMA CREDIT PLC (GB) | 2023-01-05 | — | — | US | claimed |
| EP-3625368-B1 | METHODS FOR ASSESSING THE RISK OF DEVELOPING PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY CAUSED BY JOHN CUNNINGHAM VIRUS BY GENETIC TESTING | PML SCREENING LLC (US) | 2022-11-09 | — | — | EP | claimed |
| US-20220233466-A1 | TERAMEPROCOL AND NORDIHYDROGUAIARETIC ACID (NDGA) DERIVATIVES AS CORONAVIRUS ANTI-VIRAL AGENTS | ERIMOS PHARMACEUTICALS, LLC | 2022-07-28 | — | — | US | claimed |
| US-20220096818-A1 | Compositions And Methods For Increasing Cancer Cell Sensitivity To Alternating Electric Fields | BIOPHARMA CREDIT PLC (GB) | 2022-03-31 | — | — | US | claimed |
| WO-2022029628-A1 | COMPOSITIONS AND METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | NOVOCURE GMBH (CH) | 2022-02-10 | — | — | WO | claimed |
| EP-1841401-A1 | REDUCTION OF HAIR GROWTH WITH SURVIVIN INHIBITORS | The Gillette Company (US) | 2007-10-10 | — | — | EP | claimed |
| WO-2006069192-A1 | REDUCTION OF HAIR GROWTH WITH SURVIVIN INHIBITORS | THE GILLETTE COMPANY (US) | 2006-06-29 | — | — | WO | claimed |
| US-20060135461-A1 | Reduction of hair growth | GILLETTE COMPANY, THE | 2006-06-22 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220233466-A1 | TERAMEPROCOL AND NORDIHYDROGUAIARETIC ACID (NDGA) DERIVATIVES AS CORONAVIRUS ANTI-VIRAL AGENTS | PTGES, PTGES2, ACE2 | ALOX15 33/4885ALOX12 30/4885FOS 2775/4885 |
| US-20060135461-A1 | Reduction of hair growth | MKI67, NGF, KRT18 | ALOX15 2146/4885ALOX12 2410/4885FOS 565/4885 |
| US-12594421-B2 | Compositions and methods for increasing cancer cell sensitivity to alternating electric fields | PTK2, GSK3B, MTOR | ALOX15 3830/4885ALOX12 3732/4885FOS 497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.